Suspected anaphylaxis to the COVID-19 vaccines in the UK is reported at a rate of about 11-17 per million doses for the Pfizer/ BioNTech and AstraZeneca vaccines respectively [MHRA yellow card data, 23 June 2021]. This will underestimate the true size of the problem as cases are not reported and 43% of these data relate to second doses. However, after investigation, true allergy is rarely found and many are not IgE mediated 1 and are often labelled immunogenic reactions. Recent studies have shown successful revaccination in patients who had suspected allergic reactions to their first dose. 2,3 Polysorbate 80 (PS80) is the potentially allergenic excipient in the AstraZeneca and Janssen/Johnson and Johnson COVID-19 vaccines. PS80 is used as an excipient in many drugs (including some vaccines, e.g., some influenza vaccines) and as a food additive and is thus widely tolerated. 4 There have been cases of clinical reactivity

No abstract

No abstract

No abstract

No abstract